Recent Updates
Recently added Catalysts
BTAI Negative Sentiment Score: 20/100

BioXcel Therapeutics, Inc Investors: Please contact the Portnoy Law Firm to recover your losses; September 5, 2023 deadline

Key Takeaway: The Portnoy Law Firm has announced a class action lawsuit against BioXcel Therapeutics, Inc. (BTAI) on behalf of investors who purchased securities between December 15, 2021, and June 28, 2023. The lawsuit alleges that the company made materially false statements and withheld critical information about its business operations and regulatory compliance. Specific failures include inadequate internal controls and misleading communications submitted to the FDA. Investors are encouraged to contact the firm for legal evaluations and potential recovery of losses due to these alleged misrepresentations.

Market Sentiment Analysis

CONCERNS & RISKS

  • The lawsuit claims that BioXcel made materially false and deceptive statements.
  • Investors were not informed of serious issues regarding the Company's internal controls.
  • There were failures in compliance with approved protocols by the principal investigator.
  • The company allegedly fabricated correspondence submitted to the FDA.

Full Press Release Details

Investors can contact the law firm at no cost to learn more about recovering their losses
​LOS ANGELES, Aug. 14, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI). investors that a lawsuit filed on behalf of investors that purchased BioXcel securities between December 15, 2021 and June 28, 2023, both dates inclusive (the “Class Period”).
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
The lawsuit filed in this class action asserts that during the designated period, the Defendants made statements that were materially false and/or deceptive, and also neglected to disclose crucial negative information about the Company's business, operations, and future prospects. Specifically, the Defendants failed to inform investors of the following: (1) the Company's inadequate internal controls concerning adherence to protocols and data integrity; (2) the failure of the Company's principal investigator to comply with the approved informed consent form from the Institutional Review Board; (3) the inadequate maintenance of complete case histories for certain patients whose records were reviewed by the FDA; (4) the fabrication of email correspondence between the Company's principal investigator and a pharmacovigilance safety vendor, which was then submitted to the FDA; (5) the detrimental impact of these issues on the Company's ability to obtain regulatory approval for BXCL501 as a treatment for agitation associated with dementia in probable Alzheimer's disease patients; and (6) as a result of the aforementioned issues, the Defendants' positive statements about the Company's business, operations, and prospects were significantly misleading and lacked a reasonable basis.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
Attorney Advertising

Tags

Frequently Asked Questions

What is the purpose of the lawsuit against BioXcel?

The lawsuit aims to address false statements and undisclosed negative information from BioXcel during a specific period.

How can investors contact the Portnoy Law Firm?

Investors can reach attorney Lesley F. Portnoy by phone at 844-767-8529 or email lesley@portnoylaw.com.

What is the time frame for the Class Period relevant to the lawsuit?

The Class Period for the lawsuit includes purchases from December 15, 2021, to June 28, 2023.

What issues were highlighted in the lawsuit against BioXcel?

The lawsuit highlights inadequate internal controls, compliance failures, and misleading statements about BioXcel's prospects.

What can investors expect from the Portnoy Law Firm?

The firm offers a complimentary case evaluation to discuss options for recovering investment losses.

Last updated: Aug 14, 2023